DAVITA INC.

NYSE: DVA·Denver, Colorado·

Price
$174.22
Base IV
$339.45

Valuation snapshot

Below bear case

At $174.22, the price is below even our bear case of $238.28.

Values per share, from an .

No growth
…
Loading earnings power
Base case
$339.45
above today's price · range $238.28–$459.48
Price vs base case
49% below
$174.22 against $339.45
Base casevalued by DCF
Price vs base
Priceclose 11‑16

The price has fallen 9.6% since this valuation was struck on 2026-11-05, so some of the gap opened up after these figures were set.

Whisker on the base case runs bear $238.28 to bull $459.48. Values per share.

Price against each value

Bear case
$238.28
Price 27% below
No growth
…
—
Base case
$339.45
Price 49% below
Researched bygemini-3.8-flash-medium
Valuation Nov 5, 2026 · Price as of Nov 16, 2026How we got here

What does Davita do?

DaVita provides dialysis treatments and integrated kidney care services to patients with chronic kidney disease and end-stage renal disease to manage and slow disease progression.

It brought in $14.2B of sales in the 12 months to Sep 2026.

Led by Javier J. Rodriguez, Chief Executive Officer since 2019. DaVita Inc. DEF 14A Proxy Statement

Industry
Healthcare
Based in
Denver, Colorado
Trades on
NYSE as DVA

Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 6¢ was left as profit after every cost, interest and tax. The biggest cost is everything else it takes to operate, 73¢ of every dollar.

  • Admin costs12¢
  • Everything else it takes to operate73¢
  • Interest and other costs4¢
  • Tax2¢
  • Other items after tax2¢
  • Left as profit6¢
Totals of the four quarters to Sep 2026, from the company's own filings. The split by product is from the latest fiscal year.

Who pays Davita, and for what?

DaVita provides dialysis and related lab services, mainly through U.S. outpatient centers, hospitals and home programs. It also offers kidney care management and runs dialysis centers internationally. It earns most of its revenue from U.S. dialysis services.

Patients receive its care, while government health programs, private insurers, hospitals and health plans pay for most services.

  • U.S. dialysis

    86%

    Dialysis and related lab services, primarily in outpatient centers, as well as home and hospital dialysis.

  • Other ancillary services

    14%

    Integrated kidney care, international dialysis operations, clinical research, transplant software and other services.

Share of the latest fiscal year's sales, as the company reports it.

Where its work physically happens, beyond headquarters:

  • DaVita Labs — DeLand, United States. This laboratory provides specialized kidney disease testing for more than 200,000 DaVita dialysis patients across the United States each year.
  • DaVita International headquarters — London, United Kingdom. This office provides strategic and operational support for DaVita’s dialysis operations outside the United States.
See them on the globe

DaVita 2025 Form 10-K

How is the business doing?

Sales grew from $11.6B in 2020 to $13.6B in 2025, about 3% a year.

Running the business leaves about 15¢ of each sales dollar as operating profit, about the same as 15¢ in 2020.

After paying for its upkeep and new investment, it had $1.3B of cash to spare in the 12 months to Sep 2026.

Sales$13.6B
20172025
Operating margin15%
20172025
Free cash flow$1.3B
20172025
Each bar is one fiscal year (2017–2025), summed from four published quarters; the latest is highlighted.

What does management say it's aiming for?

DaVita says it aims to be the preferred provider, partner and employer.

“To be the Provider, Partner, and Employer of Choice.”

About DaVita Kidney Care

Who is responsible for the plan?

  • Javier J. RodriguezChief Executive Officer

    He oversees DaVita's strategic direction, enterprise operations, and global kidney care services. DaVita generates revenue primarily by providing dialysis and related lab services to patients suffering from end-stage renal disease.

  • David MaughanChief Operating Officer, DaVita Kidney Care

    He oversees domestic kidney care operations across DaVita's network of outpatient dialysis centers, hospital services, and home modalities. Dialysis operations provide the patient treatments that generate the vast majority of DaVita's operating revenue.

  • Madhu NarasimhanChief Information Officer

    She oversees DaVita's enterprise technology strategy, digital transformation, and health technology platforms including the Center Without Walls clinical operating system. Proprietary clinical technology systems support care coordination, clinical workflows, and patient data management across dialysis operations.

Roles checked November 14, 2026.

What management says it is working on now:

  • Improve kidney care

    The company describes a focus on care that is more preventive and coordinated, with better outcomes and personalized support across the kidney health journey.

    DaVita 2025 Form 10-K
  • Expand integrated kidney care

    DaVita is developing care management and payment arrangements that coordinate providers and aim to improve outcomes and reduce overall care costs.

    DaVita 2025 Form 10-K
  • Support home dialysis

    The company provides equipment, training and follow-up support for patients receiving dialysis at home, and identifies home-based dialysis as a strategic initiative.

    DaVita 2025 Form 10-K
  • Manage costs and staffing

    DaVita says it is continuing cost-control efforts, including improving labor productivity, amid rising labor and supply costs and competition for clinical staff.

    DaVita 2025 Form 10-K
  • Grow international operations

    The company reports growth in international dialysis patients and centers and expects operating income growth in its international business.

    DaVita 2025 Form 10-K
Adjusted operating income, 2026
$2.15 billion to $2.25 billion
DaVita Inc. 2nd Quarter 2026 Results
Adjusted diluted net income per share, 2026
$14.10 to $15.20
DaVita Inc. 2nd Quarter 2026 Results
Free cash flow, 2026
$1.0 billion to $1.25 billion
DaVita Inc. 2nd Quarter 2026 Results
U.S. dialysis treatment growth, 2026
Near the top of the prior 0.25% to 0.50% guidance range
DaVita Q2 2026 Earnings Call Transcript
Goals in management's own numbers. A target is a promise, not a result.

What's changing right now?

Growth is holding steady. In Q3 2026 it sold 5% more than a year earlier. The year before, quarters averaged 6%.

Its operating margin is about where it was a year ago, 14¢ per sales dollar.

Since Oct 2026 the share price has fallen 10%, from $193.31 to $174.22.

Bull $459.48Base $339.45Bear $238.28Oct 30Nov 16 · $174.22
Daily closing prices we have recorded, set against our bear-to-bull range. Our price records start October 30, 2026.

Recently

Coming up

  • End of 2026

    Medicare phosphate-binder payment transition

    The temporary Medicare add-on payment for phosphate binders is currently scheduled to end; how the drug is handled in the bundled payment afterward could affect operating results.

    DaVita 2025 Form 10-K
  • Expected October 29, 2026

    Third-quarter 2026 results

    DaVita is expected to report its next quarterly results, which may provide an update on treatment volumes, payment rates and its 2026 outlook.

    DaVita Q2 2026 Earnings Call Transcript & Audio

Our own estimate moved too: the base case went from $248.97 to $339.45 a share between our last two valuations.

What could go wrong?

No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.

  1. Payment rates and rules can change

    Government programs set many U.S. dialysis payment rates, and changes to reimbursement or healthcare rules could reduce revenue or require costly changes. The company also faces legal inquiries and compliance requirements.

    From the company's own filingsWould hit how fast sales growDaVita 2025 Form 10-K

  2. Fewer commercially insured patients

    Commercial insurance generally pays more than government programs and generates nearly all company profit. If fewer patients have this coverage, or negotiations lead to lower rates, results could suffer.

    From the company's own filingsWould hit how fast sales growDaVita 2025 Form 10-K

  3. Labor and supply costs

    Dialysis care requires clinical staff and medical supplies. Rising wages, staff shortages or supply disruptions could increase costs faster than payment rates rise.

    From the company's own filingsWould hit how much of each sale it keepsDaVita 2025 Form 10-K

  4. Lower treatment volumes

    Patient deaths, missed treatments, slower growth in kidney failure, transplants or new treatments could reduce dialysis demand and treatment volumes.

    From the company's own filingsWould hit how fast sales growDaVita 2025 Form 10-K

  5. Cybersecurity and information systems

    The company experienced a cybersecurity incident in 2025 and relies on its own and third-party systems for clinical, billing and collection work. Further disruption or data exposure could affect operations and cash collection.

    From the company's own filingsWould hit how fast sales growDaVita 2025 Form 10-K

  6. Debt and interest costs

    DaVita has substantial debt and must generate cash to service it while funding other needs. Interest rates, refinancing conditions or weaker cash generation could raise the burden.

    From the company's own filingsWould hit how much it has to reinvestDaVita 2025 Form 10-K

  7. Total U.S. dialysis patient census remained essentially flat at approximately 200,800 patients between 2023 and 2024.

    From our researchWould hit how fast sales growDaVita 2024 Form 10-K Patient Census

  8. Faster shift toward home dialysis modalities could lower physical clinic capital requirements over time.

    From our researchWould hit how much it has to reinvestDaVita Strategic Home Modality Disclosures

Is it a good business?

From 2017 to 2025 it earned between 9% and 19% on the capital invested in it, a median of 14%. Its cost of capital in the latest valuation is 6.9%; returns were above it in every one of the 9 years.

From 2017 to 2024 it earned between 4% and 773% on its shareholders' equity, a median of 61%.

Over 9 years its operating margin ranged from 12¢ to 18¢ per sales dollar, a median of 15¢.

derived computed from the filingsassumption cost of capital from the latest valuation
Return on invested capital18%
20172025

Cost of capital 6.9%

Return on invested capital is operating profit after tax (at the median effective rate, 22%) over debt plus equity less cash at each fiscal year end. Return on equity is net income over equity. Both are computed from published quarters.

It bought back shares: the count fell 11.2% in a year, so each remaining share owns a slightly bigger slice.

It owes $10.2B more than it holds in cash, about 4.8 years of operating profit.

What might it be worth?

The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .

Today a share costs $174.22. Our put its value between $238.28 and $459.48, with $339.45 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .

Bear case, $238.28

This scenario envisions that recent sales gains slow down as fewer new kidney patients enter clinics and stubborn nurse wage costs squeeze corporate profits.

Base case, $339.45

This scenario envisions that steady patient demand and modest commercial price increases keep annual sales growing at a stable mid-single-digit pace while clinic profitability holds near recent averages.

Bull case, $459.48

This scenario envisions that accelerating international expansion, successful value-based kidney care programs, and clinic automation lift sales growth and widen profit margins past recent levels.

Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.

Why the gap?

The price expects less than we do.Margin of safety: 49%

At today's $174.22, the price makes sense if sales shrink about 4.8% a year. We assume they grow 4.0%. Over the last 5 years, sales grew 4.1% a year.

−6%−4%−2%0%+2%+4%+6%Price needs −4.8%We assume 4.0%Past 5 yrs 4.1%

Or, if sales grow 4.0% as we assume, the price works with a profit margin of 10.0% (we assume 15.0%).

Keep in mind: a low price can mean investors see a risk that isn't in the filings yet. Check the Full research tab for what could go wrong.

Do you think sales will shrink?

Try your own numbers

We're moderately sure of this range: it scores 72 out of 100 on our checks. The weakest point is terminal-value dependency.

Test the assumptions

Our base value of $339.45 rests on three assumptions. Change any of them to see how the value per share responds.

  • Revenue growth, 5-year average4.0%
  • Operating margin15.0%
  • Long-term growth rate2.5%

This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.

Base estimate

$339.45 94.8%

Build